Anti-IAV HA Recombinant Antibody (D1-8) (CAT#: MRO-248CT)

Figure 1 Characteristics of the putative D1-8 antigenic site.

Western blot analysis of the D1-8/H3 HA interaction. (Top blot) The recombinant trimeric HA of A/Perth/09 proteins were disrupted in 2% SDS without (−) DTT or with (+) 100 mM DTT and then analyzed by Western blotting with MAb D1-8. (Bottom blot) A Coomassie blue-stained duplicate gel to show equal loading of HA proteins.

Benjamin, E., Wang, W., McAuliffe, J. M., Palmer-Hill, F. J., Kallewaard, N. L., Chen, Z., ... & Zhu, Q. (2014). A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head. Journal of virology, 88(12), 6743-6750.

Figure 2 Therapeutic efficacy of D1-8 compared to oseltamivir in an influenza virus mouse model late in infection.

Mice received a single intraperitoneal injection of D1-8 (2.5 mg/kg) 4 days after infection or 25 mg/kg of oseltamivir, given orally twice a day (50 mg/kg/day) for 5 days, with dosing initiated 4 days after infection. Mice were monitored for 14 days for body weight loss. Mean change in body weight is expressed as a percentage of the baseline body weight. Error bars represent 95% confidence intervals

Benjamin, E., Wang, W., McAuliffe, J. M., Palmer-Hill, F. J., Kallewaard, N. L., Chen, Z., ... & Zhu, Q. (2014). A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head. Journal of virology, 88(12), 6743-6750.